We report two cases of severe alloimmune hemolysis after hematopoietic stem cell (HSC) transplant resulting from an anti-Jk a . The time course of hemolysis and Jk phenotypes of the donor and recipient in the cases reported suggest that the antibody was produced by donor-derived passenger lymphocytes. Retrospective analysis of the blood bank records of all allogeneic HSC transplant patients at Barnes-Jewish Hospital from 1994 to 1999 suggests that the incidence of alloimmune hemolysis due to incompatibilities involving non-ABO or RhD red cell antigens is very low, approximately 1%. In one patient, the duration of hemolysis was shortened significantly by performing red cell exchange at the first sign of intravascular hemolysis. Bone Marrow Transplantation (2001) 27, 1305-1310. Keywords: allotransplantation; hemolysis; alloantibodies; stem cells Delayed immune hemolysis is an uncommon, but serious complication of HSC transplantation. Pretransplant clinical consideration is usually given only to ABO and Rh compatibility between the donor and recipient.
Delayed immune hemolysis is an uncommon, but serious complication of HSC transplantation. Pretransplant clinical consideration is usually given only to ABO and Rh compatibility between the donor and recipient. [1] [2] [3] [4] The occurrence of immune hemolyis in HSC transplant recipients who receive ABO or RhD-mismatched marrow has been estimated to be approximately 10% to 15%. 3 For example, in cases of major ABO mismatch, care is taken to red cell deplete the stem cell product prior to transplant. In the absence of pre-existing alloantibodies to non-ABO antigens in the donor or recipient, no further consideration is given prior to transplant to a potential non-ABO/RhD antigen mismatch.
There are only a handful of reports in the literature reporting occurrences of non-ABO alloimmunization after allogeneic transplantation and only a few of these cases occurred following transplantation of HSCs derived either from bone marrow (BM) or peripheral blood mononuclear cells (PBMC) isolated by apheresis. [5] [6] [7] [8] [9] These reports suggest that, in contrast to patients with posttransplant hemolysis due to mismatches in the ABO system in whom hemolysis is usually moderate, non-ABO alloimmune hemolysis in the post HSC transplant setting was associated with episodes of severe hemolytic anemia presenting difficult clinical management issues. 8 No estimates of the frequency of non-ABO/RhD red cell alloimmunization in the post-transplant setting are available in the published literature.
We present two case reports of severe immune hemolytic anemia after allogeneic HSC transplant resulting from donor-derived anti-Jk a . We also retrospectively reviewed the blood bank records of all patients at Barnes-Jewish Hospital who underwent allogeneic HSC transplantation (either BM or PBMC) between January 1994 and December 1999 to determine the incidence of non-ABO alloantibodymediated hemolysis in this population.
Case 1
The first patient was a 37-year-old white male with Philadelphia chromosome positive chronic myelogenous leukemia who presented with a WBC of 31 000. He was managed with hydroxyurea with adequate control for 2 years. Upon progression, a decision was made to proceed with a 6/6 HLA-matched unrelated donor male BM-derived HSC transplant. The conditioning regimen consisted of cyclophosphamide (60 mg/kg daily) and single dose total body irradiation (TBI) with 550 cGy. The blood type of the patient was B− and donor was A+. Prior to transplant neither the patient nor the donor had any detectable alloantibodies to minor red cell antigens. After the HSC transplant, the patient received seven platelet transfusions; a portion of these (over 800 ml of plasma in total) were from out-of-group (A−) apheresis platelets. On post-transplant day (PTD) 9, the Hct had declined to 33% from an admission Hct of 44% and the patient developed a low-grade fever. By PTD 12, the patient began experiencing severe pruritus, jaundice and continued fever, in the setting of myeloid engraftment and acute skin GVHD (grade III). The Hct continued to decline over the ensuing days and could not be supported with red cell transfusions of O− units (see hemoglobinuria and his plasma was bronze-colored; both signs were consistent with intravascular hemolysis. The blood sample typed as mixed field in a blood bank work-up on PTD 14; the red cell eluate contained anti-B (believed to be from passive transfer of out-of-group platelets or, alternatively, due to passenger lymphocytes, see summary in Table 1 ). At this point, the patient had received eight O− units of red cells, but continued to have active hemolysis. The patient underwent two plasma apheresis procedures, each processing 150% of blood volume, to remove the anti-B red cell antibodies that were presumed to be the cause of his intravascular hemolysis. After apheresis, the patient Standard serologic methods were used for antibody investigations. Antibodies were detected by albumin or low ionic strength saline additive indirect, antiglobulin tests using patient serum. We performed ABO and RhD blood typing, antibody screening test and antibody identification using commercial reagents and the manufacturer's directions according to previously described methods. The DAT was performed on red cells from EDTA samples using antiglobulin reagents that were polyspecific and that contained anti-IgG and anti-C3d according to standard methods. RBC eluates were prepared by acid elution. The IgG and IgM components of the antibodies were determined by testing the sera before and after treatment with dithiothreitol.
received four additional units of O− blood with only a temporary increase in Hct. Over the next 24 h the patient continued to have a rapidly declining Hct and rising LDH. Since the patient had received numerous transfusions of O− units without stabilization of his Hct, it was suspected that the identity of the responsible alloantibody had not yet been determined. As a result, the patient's sample from PTD 14 was re-analyzed using polyethelene glycol ( Around that time, his bilirubin and LDH declined dramatically, suggesting resolution of his acute hemolytic crisis.
Other interventions such as red cell exchange were not pursued.
Case 2
The second patient was a 39-year-old female diagnosed in 1995 with non-Hodgkin's lymphoma, stage IV, with confirmed bone marrow disease. The patient was observed until progression in 1997 when she received chemotherapy and subsequently did well until recurrence in 1999 with bulky disease. She received additional chemotherapy and was admitted for an allogeneic PBMC transplant from a 6/6 HLA-matched male sibling several months later. Both the patient and donor's blood type were O+. Although the donor's transfusion history was not documented, at the time of transplantation neither the patient nor the donor had any detectable red cell alloantibodies. The patient's conditioning regimen consisted of cyclophosphamide (60 mg/kg each day for 2 days) and a single dose of TBI (550 cGy). After transplant, the patient received two scheduled, prophylactic granulocyte products from her transplant donor as part of an investigational protocol. Each granulocyte product contained small amounts of red cells (4 to 15 cc). One single donor platelet product and two units of O− red cell units (see Figure 2 for graph of laboratory data) were also administered during this time. On PTD 6, the patient's absolute neutrophil count was 28 and increased to 207 on PTD 8. On PTD 11, patient's type and crossmatch specimen revealed a positive DAT (see Table 2 for a summary of immunohematologic monitoring). Anti-Jk a was identified in the plasma and the eluate. At that time, a retrospective analysis of the patient's and donor's red cell samples prior to transplant revealed the patient to be Jk a + and the donor to be Jk a −. The patient's cyclosporine levels were increased to 215 mg and the patient was started on methylprednisolone at 80 mg per day. On PTD 13 the patient began complaining of increasing fatigue and her laboratory parameters indicated worsening intravascular hemolysis and signs of renal failure (see Standard serologic methods were used for antibody investigations. Antibodies were detected by albumin or low ionic strength saline additive indirect, antiglobulin tests using patient serum. We performed ABO and RhD blood typing, antibody screening test and antibody identification using commercial reagents and the manufacturer's directions according to previously described methods. The DAT was performed on red cells from EDTA samples using antiglobulin reagents that were polyspecific and that contained anti-IgG and anti-C3d according to standard methods. RBC eluates were prepared by acid elution. The IgG and IgM components of the antibodies were determined by testing the sera before and after treatment with dithiothreitol.
Bone Marrow Transplantation Figure 2 for graphs of laboratory findings). Serum haptoglobin, which was within normal limits on PTD 11, was undetectable on PTD 13. The patient's urine showed 3+ occult blood with no red cells and her serum was bronzecolored, consistent with free hemoglobin resulting from intravascular hemolysis. Taking into consideration the number of units of Jk a − and Jk a + red cell units the patient had received since transplant, it was calculated that up to five units of Jk a + cells remained in vivo at that time. To prevent complications resulting from hemolysis of these remaining units, therefore, the decision was made to perform a red cell exchange. Prior to initiation of red cell exchange, a repeat sample for compatibility testing was submitted to the blood bank. Surprisingly, a new alloantibody, an anti-E, was detected in this sample in the plasma and eluate in addition to the previously present anti-Jk a , providing further rationale to proceed with the red cell exchange.
The patient underwent red cell exchange on day 14 with irradiated, leukocyte-reduced, CMV-negative units that were Jk a -negative, E-negative, Coombs crossmatched type O red cell units. The patient's symptoms and laboratory parameters were largely corrected after the procedure and there were no further complications from intravascular hemolysis.
Results
To determine the incidence at our institution of non-ABO alloantibodies after allogeneic HSC transplant, we examined blood bank laboratory results for all allogeneic HSC transplantations performed over a 6-year period between January 1994 and December 1999. A total of 427 allogeneic HSC transplants were performed at Washington University/Barnes-Jewish Hospital during this period. Of these, five patients (incidence of ෂ1%) were identified to have hemolysis involving non-ABO red cell alloantibodies (summarized in Table 3 ). Of these patients, one had antiJk a and another had both anti-Jk a and anti-E (both presented as case reports above), a third had anti-D and anti-s, a fourth patient had anti-E, and a fifth patient had anti-s and an unidentified, nonspecific antibody. The time course of appearance of the alloantibodies ranged from PTD 9 to 27.
Discussion
The time course of appearance of the non ABO/Rh alloantibodies in our patients are similar to the time course (9 to 16 days) predicted by cases in the literature of the appearance of anti-ABO/RhD antibodies in the setting of post-HSC transplant. The majority of the cases of immune hemolyis due to ABO/RhD mismatches are moderate in severity and the clinician is alerted for signs of hemolytic anemia in such patients. In contrast, cases of non-ABO immune hemolysis frequently involve donors and recipients with no prior evidence of alloantibodies, thus making it impossible to predict a priori those patients who are at risk. [6] [7] [8] [9] [10] It is important to note that both of our patients developed anti-Jk a . The in vitro detection and characteriz- ation of the Kidd antibodies can be among the more difficult tasks since the success of detection is often method dependent. 11 For example, testing performed by the gel card system (see Table 1 ) failed to detect the antibody for patient No. 1. It is not uncommon to find that an individual who once had an anti-Jk a to have no serologically demonstrable antibody present in serum a few months after the antibody was originally identified. 11 This may explain why both donors of the cases presented had a negative screen prior to transplant. Furthermore, anti-Jk a can result in severe intravascular and extravascular hemolysis as exemplified by the two cases presented above.
The causes of immune hemolysis in the post-HSC transplant setting include: (1) pre-existing antibodies either in the recipient and/or donor; (2) production of antibodies by residual recipient lymphoid cells that survived ablative preconditioning; (3) production of antibodies by adoptively transferred donor lymphocytes in the graft; (4) production of antibodies by donor-derived lymphocytes after donor engraftment. Immune hemolysis resulting from the first cause would be predicted to occur immediately after transplant. In contrast, the fourth mechanism would be to predict hemolysis to occur several weeks after transplant. All but one of the cases thus far reported have attributed the development of non-ABO alloantibodies arising after HSC transplant to donor-derived lymphocytes present in the graft. One case report in the literature attributed the source of the numerous alloantibodies (anti-K, anti-Jk b , anti-M) to residual recipient lymphocytes based on analysis of donor and recipient red cell phenotypes. The patient was reported to experience severe, repeated episodes of immune hemolysis despite numerous plasma exchange procedures and eventually died with graft failure. 8 The cause of immune hemolysis in the two patients presented above is believed to be due to production of antibodies by donor-derived lymphocytes transferred with the graft. Both patients received non-T cell-depleted HSC grafts. Although both donors were male with no documented previous transfusions, the rapidity of the appearance of the alloantibodies strongly suggests a secondary immune response. It is possible, but unlikely, that the transfusion history is incorrect. A negative antibody screen in such donors resulting from loss of red cell alloantibodies, especially the Kidd antibodies, over time has been previously documented. [12] [13] [14] Alternatively, the development of red cell alloantibodies involving mechanisms distinct from alloimmunization, such as post-infectious causes, has also been previously reported. 15, 16 Based on chimerism analysis, both patients were shown to have successfully engrafted the donor cells (Ͼ99% donor as determined by PCR donor and recipient analysis of specific VNTRs of post-transplant bone marrow) and did not have any recurrent episodes of hemolysis.
We present two patients for whom the development of non-ABO/D alloimmune hemolysis was abrupt in onset and severe with rapidly dropping hemoglobin, signs of intravascular and extravascular hemolysis, and renal failure. For case 1, our primary approach was to perform two plasma exchange procedures in order to remove passively acquired anti-B which was presumed to be responsible for the hemolytic crisis. If we had successfully identified the anti-Jk a as
Bone Marrow Transplantation the most probable source of hemolysis, then the patient may have been more successfully treated with a red cell exchange. For case 2, we were able to significantly reduce the period and extent of hemolysis by performing red cell exchange to remove the majority of the recipient cells that were the target of the alloantibody. Our analysis suggests that the incidence of alloimmune hemolysis due to non-ABO/D antibodies is very low (ෂ1%). These cases illustrate that patients who have evidence of severe hemolysis due to donor lymphocyte-derived alloantibodies, particularly Jk a , should be considered for aggressive intervention, including red cell exchange. These cases also emphasize the importance of close immunohematologic monitoring by the blood bank staff and clinicians of patients undergoing allogeneic transplantation, even in the absence of ABO/RhD mismatch.
